Fig. 6: RTKs promote cancer cells sensitivity to ferroptosis in vivo.
From: Oncogenic RTKs sensitize cancer cells to ferroptosis via c-Myc mediated upregulation of ACSL4
A Schematic illustration of the experimental design of mouse xenograft model. B High level of RTKs sensitize cancer cells to ferroptosis-inducing treatment. Representative photographs of tumors in the vehicle group and IKE group. The indicated B16-F10 cells were injected subcutaneously into C57BL/6 mice. C Growth curves of tumors after drug treatment. D Tumor weight after drug treatment. E High level of RTKs increases MDA level of cancer cells upon ferroptosis-inducing treatment. F Working model. RTKs/RAS/RAF/c-Myc axis is activated during ferroptosis, which results in upregulation of ACSL4 expression and enhancing the sensitivity of cancer cells to ferroptosis. All data are mean ± SD. n = 5. *P < 0.05, **P < 0.01, ***P < 0.001 by two-tailed t-test.
